drugset / Trial / NCT01134705

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

NCT01134705 ↗

Phase 3 Completed 474 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of perennial allergic rhinitis.

Timeline

Start
2010-05
Primary completion
2010-10
Completion
2010-10

Outcome

Met primary endpoint

registry analysis (superiority or other test); BDP HFA 320 µg/Day vs Placebo; p <0.001; LS Mean Difference -0.84 (95% CI -1.2 to -0.5) NCT01134705 ↗

paper Treatment with BDP nasal aerosol showed significantly greater improvement in average A.M. and P.M. rTNSS compared with placebo PMID 22737708 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject beclomethasone dipropionate Other / unclassified 320 ug Intranasal